Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment

Radiation Oncology

Fei Han¹  Tai-Xiang Lu²  Ying Guan²  Shuai Liu²  Feng-Hua Wang²  Lei Zeng²  Yun-Ming Tian² 

[1] Department of Radiation Oncology, Cancer Center of Sun Yat-Sen University, 651 Dong Feng, Road East, Guangzhou 510060, Guangdong Province, PR China;State Key Laboratory of Oncolo-gy in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China

关键词: Local therapy;    Lactate dehydrogenase;    Response;    Prognosis;    Liver metastasis;    Nasopharyngeal carcinoma;   

Others  :  829690
DOI  :  10.1186/1748-717X-8-272

 received in 2013-04-24, accepted in 2013-11-16,  发布年份 2013

【 摘 要 】

Purpose

To retrospectively analyze the prognosis of patients with nasopharyngeal carcinoma (NPC) initially presenting with liver metastasis, in order to identify independent prognostic factors to facilitate management of treatment.

Methods

Eighty-five patients with untreated NPC and synchronous liver metastasis, initially diagnosed between January 2000 and December 2009, were selected for this retrospective study. Seventy-eight received systemic chemotherapy, 32 underwent subsequent radiotherapy of the primary tumor, and 18 received local therapy for metastatic lesions. Clinical features, laboratory parameters and treatment modalities were compared by univariate and multivariate analyses.

Results

The median survival time was 19.0 months and the 3-year overall survival rate was 14.1%. The overall response and disease control rates were 70.4% and 86.4%, respectively. Significant predictors of short survival were KPS ≤ 70 (P = 0.03), serum lactate dehydrogenase levels >245 IU/l (P = 0.01) and poor response to chemotherapy (P < 0.01). In contrast, significantly longer survival rates were achieved by patients having at least six chemotherapy cycles compared to those receiving <6 cycles (3-year OS: 18.3% vs. 7.1%; P < 0.01), and patients receiving radiotherapy of the primary tumor following complete or partial response to chemotherapy (3-year OS: 30.8% vs. 3.8%, P < 0.01).

Conclusions

Five key independent factors were identified and sub-classified as potential prognostic indicators for NPC with liver metastases. Progressive treatments of systemic chemotherapy and radiotherapy at the primary tumor could prolong survival in the subset of patients having fewer negative prognosticators.

【 授权许可】

   
2013 Tian et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Yu MC, Yuan JM: Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:421-429.
• [2]Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15:1765-1777.
• [3]Lee AW, Ng WT, Chan YH, Sze H, Chan C: The battle against nasopharyngeal cancer. Radiother Oncol 2012, 104:272-278.
• [4]Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
• [5]Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M, Ho JH: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992, 23:261-270.
• [6]Yeh SA, Tang Y, Lui CC, Huang EY: Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma: benefits of primary radiotherapy. Jpn J Clin Oncol 2006, 36:132-136.
• [7]Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, Boussen H, Errihani H: Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2011, 128:79-85.
• [8]Teo PM, Kwan WH, Lee WY, Leung SF: Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996, 77:2423-2431.
• [9]Ong YK, Heng DM, Chung B, Leong SS, Wee J, Fong KW, Tan T, Tan EH: Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 2003, 39:1535-1541.
• [10]Toh CK, Heng D, Ong YK, Leong SS: Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005, 92:1382-1387.
• [11]Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW, Chan AT: Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004, 101:300-306.
• [12]Ma J, Wen ZS, Lin P, Wang X, Xie FY: The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases. Chin J Cancer 2010, 29:787-795.
• [13]Pan C, He N, Zhao M, Gu Y, Huang Z, Li W, Xia Y, Wu P: Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Med Oncol 2011, 28:1349-1355.
• [14]Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000, 18:1324-1330.
• [15]Chou CW, Liu JM, Wu MF, Li AF: Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature. Jpn J Clin Oncol 1997, 27:336-339.
• [16]Setton J, Wolden S, Caria N, Lee N: Definitive treatment of metastatic nasopharyngeal carcinoma: report of 5 cases with review of literature. Head Neck 2012, 34:753-757.
• [17]Choo R, Tannock I: Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx: a review of the Princess Margaret Hospital experience. Cancer 1991, 68:2120-2124.
• [18]Wang CT, Cao KJ, Li Y, Xie GF: Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis. Ai Zheng 2007, 26:212-215.
• [19]Gillams AR, Lees WR: Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009, 19:1206-1213.
• [20]Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759-766.
• [21]Nicolaides C, Fountzilas G, Zoumbos N, Skarlos D, Kosmidis P, Pectasides D, Karabelis A, Giannakakis T, Symeonidis A, Papadopoulos A, Antoniou F, Pavlidis N: Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin’s lymphoma prognostic index: a Hellenic Cooperative Oncology Group Study. Oncology 1998, 55:405-415.
• [22]Stokkel MP, Van Eck-Smit BL, Zwinderman AH, Willems LN, Pauwels EK: Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol 1998, 124:215-219.
• [23]Liaw CC, Wang CH, Huang JS, Kiu MC, Chen JS, Chang HK: Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. Acta Oncol 1997, 36:159-164.
• [24]Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, Liu LZ, Li L, Lin AH, Ma J: Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys 2012, 82:359-365.
• [25]Jin Y, Ye X, Shao L, Lin BC, He CX, Zhang BB, Zhang YP: Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur J Cancer 2013, 49:1619-1626.